ABSTRACT A polypeptide was purified from rat hypothalamic extracts on the basis of its high intrinsic activity to release corticotropin (ACTH) from cultured rat anterior pituitary cells and its immunoactivity in a radioimmunoassay directed against the NH2 terminus (residues 4-20) of ovine hypothalamic corticotropin-releasing factor (CRF). Based on Edman degradation, peptide mapping, and amino acid analysis, the primary structure of this rat CRF was established to be: H-Ser-Glu-Glu-Pro-Pro-IleSer-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-GluMet-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-ArgLys-Leu-Met-Glu-Ile-Ile-NH2. The hypophysiotropic potency of synthetic rat CRF did not deviate significantly from the potencies of the isolated native peptide or of synthetic ovine CRF. The close structural relationship between rat and ovine hypothalamic CRF is indicated by an 83% sequence homology.
Harris proposed that the neuroregulation of adrenocorticotropic hormone (ACTH; corticotropin) may be mediated by a substance later termed corticotropin-releasing factor (CRF), which reaches the adenohypophysis by the hypothalamic-hypophysial portal system (1) . Early experimental observations by Guillemin and Rosenberg (2) , and Saffran and Schally (3), supported the presence of such factors in the hypothalamus that would increase the rate of ACTH secretion by the pituitary gland incubated in vitro or maintained in organ culture. More than 25 years later, ovine CRF (oCRF) was isolated (4, 5) , characterized (5, 6) , and synthesized (7) . Subsequently the amino acid sequence of the protein precursor of oCRF was deduced from the cDNA (8) . With the availability of synthetic oCRF and antibodies raised against it, various aspects of oCRF's distribution and of its hypophyseal, vascular, and neural actions have been investigated (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , and immunoneutralization experiments in the rat with anti-oCRF antisera have demonstrated that this or related peptides are indeed involved in the physiologic regulation of ACTH secretion (19) . As oCRF was purified from a side fraction (5) containing only a small percentage of the total ACTH-releasing activity in ovine hypothalamic extracts (20) , it was necessary to establish the structure of the predominant CRF in fresh tissue extracts. Because of its importance as an experimental animal and because its CRF differed from oCRF with respect to immunologic and chromatographic behavior, the rat was chosen as a source of CRF. We report here the isolation, characterization, and total synthesis of rat CRF (rCRF), a 41-residue peptide belonging to the family that includes oCRF, sauvagine (21) , and urotensin 1 (22) . In view of the fact that the latter three peptides have a spectrum of biological activities on the cardiovascular and central nervous systems of the mammal with differences in relative potencies (23) (24) (25) , it was furthermore important to characterize CRF in the species in which its physiological functions have been most thoroughly investigated.
EXPERIMENTAL PROCEDURES rCRF was purified from lyophilized rat hypothalamic fragments provided by A. Parlow under the aegis of National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases. We used two separate biological tests to follow CRF activities throughout our purification schemes: (i) an in vitro method for assaying the ability of CRF to stimulate the secretion of ACTH and f3-endorphin by primary cultures of rat pituitary cells (5, 26) and (ii) a radioimmunoassay (RIA) with the C-24 antibody directed toward the NH2 terminus (residues 4-20) of oCRF and with HPLC-purified '25I-labeled CRF, [Tyr13,Nle2 ]CRF, or [Nle2 ,Tyr32]CRF as the radioligand (22) . C-24 CRF antibody was generated in a rabbit immunized with [Tyr22,Gly23]oCRF-(1-23) coupled to human a globulin by bisdiazotized benzidine. Sensitivity of the assav is <1 fmol.
Peptides were made by the solid-phase approach. t-Butvloxycarbonyl N" protection (Boc) was used throughout. Side chains were protected as follows: benzyl esters (OBzl) for both aspartic and glutamic acids, benzyl ethers (OBzl) for both serine and threonine hydroxyl groups, xanthydryl (Xan) for both asparagine and glutamine, tosyl (Tos) for both histidine and arginine, and chlorobenzyloxycarbonyl (2CIZ) for lysine. Couplings (1-2 hr) were mediated by dicyclohexylcarbodiimide in CH2Cl2 or dimethylformamide for asparagine, glutamine, and arginine derivatives. A 3-fold excess of amino acid based on the original substitution of the resin was used. Double couplings were automatically performed at residues 14, 18 , and 40. Syntheses were started with as many as 12 g of resin per run in a modified Beckman 990 B synthesizer. In that case, the peptide resin weighed 25 g and was cleaved in HF (150 ml) batchwise (8 g ) in the presence of anisole (20 ml) For purification of the synthetic peptides, cartridges fitting Waters Associates preparative liquid chromatograph 500 (LC-500) were packed with 15-to 20-um C18, C4, or phenyl silicas (300 A, Vydac). A gradient of CH3CN in TEAP buffer (27) was generated by a low-pressure Eldex gradient maker. Crude peptides (directly after HF cleavage and lvophilization) were loaded (3 g per run) through the pump; cuts were made, analyzed, and often rerun under different conditions until pure product was obtained. Desalting of the purified fractions, independently checked for purity, was achieved by using a gradient of CH3CN in 0.1% CF3COOH (28) . The center cut was lyophilized to vield Abbreviations: ACTH, adrenocorticotropic hormone or corticotropin; CRF, corticotropin-releasing factor; rCRF, rat CRF; oCRF, ovine CRF; RIA, radioimmunoassay; GH-RF, growth hormone (somatotropin)-releasing factor. 4851 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be herebv marked "advertisement" in accordance with 18 U.S.C. § 1734 solely to indicate this fact.
(10-15%) the desired product ([a]' = -93.7, concentration = 1 g/100 ml in 1% AcOH after correction of peptide content by amino acid composition).
RESULTS AND DISCUSSION Acetone defatting of the rat hypothalamic tissues and acid extraction followed by gel filtration on Sephadex G-50 has been described earlier in a scheme used for the initial purification of rat hypothalamic growth hormone (somatotropin)-releasing factor (GH-RF) (29) (Fig. 1) .
Details of the purification of batch 2 are outlined in Table 1 .
A semipreparative step (1) Problems associated with the purification of hypophysi- A homology (83%) with oCRF is present ( Fig. 2) : substitutions are found at positions 2, 22, 23, 25, 38, 39, and 41. With the exception of the position 2 substitution, oCRF and rCRF share a common 1-21 sequence, thus explaining the ability of the RIA with the C-24 antibody directed against the NH2-terminal 4-20 residues to read both CRFs well, whereas most RIAs developed against the whole oCRF sequence had been shown in several laboratories (23, 30) to only poorly detect rCRF. RIAs with the C-24 antisera have been used to detect CRF-like immunoactivity in the hypothalamus/median eminence/pituitary of sheep, dog, rat, and human (9, 13, 14) .
rCRF was synthesized in a stepwise manner on a paramethylbenzhydrylamine resin. The following sequence was assembled by using experimental procedures similar to those described earlier (32) After complete deprotection and cleavage by hydrofluoric acid, the crude preparation of rCRF was purified by using preparative HPLC techniques developed in our laboratory (35) . The synthetic peptide was shown to be greater than 98% pure by HPLC with several solvent systems and columns; it had the expected amino acid composition, and a peptide map after incubation with clostripain was generated by reverse-phase HPLC (31) .
No evidence for contaminating peptides could be shown. Native [Met(0)21'38]rCRF could be generated by H202 oxidation in 0.1% CF3COOH in the presence of 10-20% CH3CN. Svnthetic [Met(0)21 38]rCRF was generated from synthetic rCRF after H202 oxidation in 1% AcOH as reported earlier for oCRF'5.
As can be seen (Fig. 1) , both natural and synthetic peptides cannot be distinguished from their chromatographic behavior in that system. Similarly, all other tests, including sequence analysis and peptide mapping of natural and synthetic rCRF, cannot show any significant difference.
The abilities of native rCRF, synthetic rCRF, and oCRF to stimulate ACTH secretion by cultured rat pituitary cells are compared in Fig. 3 . In two assays, one of which is shown in Fig. 3 , both synthetic rCRF and oCRF and native rCRF exhibit similar potencies and intrinsic activities. In the same assay, [Met(0)21 38]rCRF was found to have only 1% of CRF potency, hence justifying our efforts to keep our extracts in the presence of reducing agents (2-mercaptoethanol) throughout the purification scheme. In the rat, rCRF has been shown to be equipotent to oCRF and to exhibit similar activities (unpublished data).
We had shown that acetvlated des-Ser-Gln-Glu-oCRF and des-Ser-Gln-Glu-Pro-Pro-oCRF had full intrinsic activity and 100% and 28% of oCRF's potency, respectively, whereas oCRF-(10-41) was almost devoid of biological activity, indicating that the NH2-terminal five or six residues were not indispensable for intrinsic activity (7) . Thus, substitution of Gln-2 in oCRF by Glu-2 in rCRF would not have been expected to modify either the spectrum of activities or potency of rCRF. Ovine CRF and human pancreatic tumor GRF (35) differ from the corresponding rat hypothalamic peptides by 17% and 33%, respectively. This marked nonalignment between mammalian regulatory peptides has not been seen for the smaller hypothalamic hypophysiotropic peptides.
